Author:
Asaadi Yasaman,Jouneghani Fatemeh Fazlollahi,Janani Sara,Rahbarizadeh Fatemeh
Abstract
AbstractBy the emergence of recombinant DNA technology, many antibody fragments have been developed devoid of undesired properties of natural immunoglobulins. Among them, camelid heavy-chain variable domains (VHHs) and single-chain variable fragments (scFvs) are the most favored ones. While scFv is used widely in various applications, camelid antibodies (VHHs) can serve as an alternative because of their superior chemical and physical properties such as higher solubility, stability, smaller size, and lower production cost. Here, these two counterparts are compared in structure and properties to identify which one is more suitable for each of their various therapeutic, diagnosis, and research applications.
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry (medical),Clinical Biochemistry,Molecular Medicine
Reference249 articles.
1. Liu JKH. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg. 2014;3:113–6.
2. Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020;12
3. (1) [cited 2021 Sep 4] Available from: /pmc/articles/PMC6973335/.
4. Antibodies Market Size, Share Trends, Growth Analysis | 2021 to 2026 [Internet]. [cited 2021 Sep 4]. Available from: https://www.marketdataforecast.com/market-reports/antibodies-market
5. Madison S. Introduction to critical ethnography. Theory Method. 2005;911(1):1–16.
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献